Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress

International Journal of Cancer

Volumn 102, Issue 6, 2002, Pages 629-637

  Lin, Chih Wei ^a   Lee, Jen Yi ^a   Tsao, Yeou Ping ^b   Shen, Che Piao ^a   Lai, Hung Cheng ^a,c   Chen, Show Li ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

E7; HPV 16; Listeria; Oral vaccine; Tumor vaccine

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; TUMOR VACCINE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG POTENCY; FLOW CYTOMETRY; GENE; IMMUNOBLOTTING; LISTERIA MONOCYTOGENES; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOUTHERN BLOTTING; T LYMPHOCYTE; TUMOR; TUMOR REGRESSION; UTERINE CERVIX CANCER; VACCINATION; VIRUS RECOMBINANT; WART VIRUS;

ADMINISTRATION, ORAL; AMINO ACID SEQUENCE; ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; LISTERIA MONOCYTOGENES; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEINS, VIRAL; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; UTERINE CERVICAL NEOPLASMS; VACCINATION; VACCINES, SYNTHETIC;

EID: 0037146759     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10759     Document Type: Article

References (60)

1. Weiskirch LM, Paterson Y. Listeria monocytogenes: A potent vaccine vector for neoplastic and infectious disease. Immunol Rev 1997;158:159-69.
2. Baldridge JR, Barry RA, Hinrichs DJ. Expression of systemic protection and delayed-type hypersensitivity to Listeria monocytogenes is mediated by different T-cell subsets. Infect Immun 1990;58:654-8.
3. Bishop DK, Hinrichs DJ. Adoptive transfer of immunity to Listeria monocytogenes: The influence of in vitro stimulation on lymphocyte subset requirements. J Immunol 1987;139:2005-9.
4. Czuprynski CJ, Brown JF, Young KM, Cooley AJ. Administration of purified anti-L3T4 monoclonal antibody impairs the resistance of mice to Listeria monocytogenes infection. Infect Immun 1989;57:100-9.
5. De Libero G, Kaufmann SH. Antigen-specific Lyt-2+ cytolytic T lymphocytes from mice infected with the intracellular bacterium Listeria monocytogenes. J Immunol 1986;137:2688-94.
6. Jensen ER, Glass AA, Clark WR, Wing EJ, Miller JF, Gregory SH. Fas (CD95)-dependent cell-mediated immunity to Listeria monocytogenes. Infect Immun 1998;66:4143-50.
7. Kaufmann SH, Hahn H. Biological functions of T cell lines with specificity for the intracellular bacterium Listeria monocytogenes in vitro and in vivo. J Exp Med 1982;155:1754-65.
8. Kaufmann SH, Hug E, Vath U, De Libero G. Specific lysis of Listeria monocytogenes-infected macrophages by class II restricted L3T4+ T cells. Eur J Immunol 1987;17:237-46.
9. Lukacs K, Kurlander RJ. MHC-unrestricted transfer of antilisterial immunity by freshly isolated immune CD8 spleen cells. J Immunol 1989;143:3731-6.
10. Magee DM, Wing EJ. Cloned L3T4+ T lymphocytes protect mice against Listeria monocytogenes by secreting IFN-gamma. J Immunol 1988;141:3203-7.
11. Mielke ME, Ehlers S, Hahn H. T cell subsets in delayed-type hypersensitivity, protection, and granuloma formation in primary and secondary Listeria infection in mice: Superior role of Lyt-2+ cells in acquired immunity. Infect Immun 1988;56:1920-5.
12. + cells, and the effect of administration of recombinant murine interferon gamma in listerial infection. J Exp Med 1990;171:1141-54.
13. Mielke ME, Niedobitek G, Stein H, Hahn H. Acquired resistance to Listeria monocytogenes is mediated by Lyt-2+ T cells independently of the influx of monocytes into granulomatous lesions. J Exp Med 1989;170:589-94.
14. Schafer R, Portnoy DA, Brassell SA, Paterson Y. Induction of a cellular immune response to a foreign antigen by a recombinant Listeria monocytogenes vaccine. J Immunol 1992;149:53-9.
15. Ikonomidis G, Paterson Y, Kos FJ, Portnoy DA. Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes. J Exp Med 1994;180:2209-18.
16. Goossens PL, Milon G, Cossart P, Saron MF. Attenuated Listeria monocytogenes as a live vector for induction of CD8+ T cells in vivo: A study with the nucleoprotein of the lymphocytic choriomeningitis virus. Int Immunol 1995;7:797-805.
17. Shen H, Slifka MK, Matloubian M, Jensen ER, Ahmed R, Miller JF. Recombinant Listeria monocytogenes as a live vaccine vehicle for the induction of protective anti-viral cell-mediated immunity. Proc Natl Acad Sci USA 1995;92:3987-91.
18. Frankel FR, Hegde S, Lieberman J, Paterson Y. Induction of cell-mediated immune responses to human immunodeficiency virus type 1 Gag protein by using Listeria monocytogenes as a live vaccine vector. J Immunol 1995;155:4775-82.
19. Slifka MK, Shen H, Matloubian M, Jensen ER, Miller JF, Ahmed R. Antiviral cytotoxic T-cell memory by vaccination with recombinant Listeria monocytogenes. J Virol 1996;70:2902-10.
20. Pan ZK, Ikonomidis G, Lazenby A, Pardoll D, Paterson Y. A recombinant Listeria monocytogenes vaccine expressing a model tumor antigen protects mice against lethal tumor cell challenge and causes regression of established tumours. Nat Med 1995;1:471-7.
21. Pan ZK, Ikonomidis G, Pardoll D, Paterson Y. Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine. Cancer Res 1995;55:4776-9.
22. Pan ZK, Weiskirch LM, Paterson Y. Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine. Cancer Res 1999;59:5264-9.
23. Jensen ER, Selvakumar R, Shen H, Ahmed R, Wettstein FO, Miller JF. Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA. J Virol 1997;71:8467-74.
24. Burghardt E, Webb MJ, Monaghan JM. Surgical Gynecological Oncology. New York: Thieme, 1993.
25. International Agency for Research on Cancer. Monograph on Cancer. Human Papillomaviruses. Geneva: World Health Organization, 1995.
26. Chen SL, Han CP, Taso YP, Lee JW, Yin CS. Identification and typing of human papillomavirus in cervical cancers in Taiwan. Cancer 1993;72:1939-45.
27. Howley PM. Role of the human papillomaviruses in human cancer. Cancer Res 1991;51:5019-22.
28. zur Hausen H, de Villiers EM. Human papillomaviruses. Annu Rev Microbiol 1994;48:427-47.
29. Chen CH, Wu TC. Experimental vaccine strategies for cancer immunotherapy. J Biomed Sci 1998;5:231-52.
30. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, Evans AS, Adams M, Stacey SN, Boursnell ME, Rutherford E, Hickling JK, et al. A recombinant vaccinia virus encoding human papillomavirus type 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996;347:1523-7.
31. Boursnell ME, Rutherford E, Hickling JK, Rollinson EA, Munro AJ, Rolley N, McLean CS, Borysiewicz LK, Vousden K, Inglis SC. Construction and characterization of a recombinant vaccina virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 1996;14:1485-94.
32. Gao L, Chain B, Sinclair C, Crawford L, Zhou J, Morris J, Zhu X, Stauss H. Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector. J Gen Virol 1994;75:157-64.
33. Lin KY, Guamieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21-6.
34. Meneguzzi G, Cerni C, Kieny MP, Lathe R. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology 1991;181:62-9.
35. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, Viscidi RP, Levitsky HI, Hedrick L, Cho KR, August JT, Pardoll DM. Engineering an intracellular pathway for major bistocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA 1995;92:11671-5.
36. d mice. Scand J Immunol 1995;42:557-63.
37. Liu DW, Tsao YP, Kung JT, Ding YA, Sytwu HK, Xiao X, Chen SL. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol 2000;74:2888-94.
38. Chen L, Mizuno MT, Singhal MC, Hu SL, Galloway DA, Hellstrom I, Hellstrom KE. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol 1992;148:2617-21.
39. Chen LP, Thomas EK, Hu SL, Hellstrom I, Hellstrom KE. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci USA 1991;88:110-4.
40. De Bruijn ML, Schuurhuis DH, Vierboom MP, Vermeulen H, de Cock KA, Ooms ME, Ressing ME, Toebes M, Franken KL, Drijfhout JW, Ottenhoff TH, Offringa R, et al. Immunization with human papillomavirus type 16 (HPV 16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class-I-restricted protection to HPV16-induced tumor cells. Cancer Res 1998;58:724-31.
41. Tuting T, DeLeo AB, Lotze MT, Storkus WJ. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur J Immunol 1997;27:2702-7.
42. Greenstone HL, Nieland JD, de Visser KE, De Bruijn ML, Kirnbauer R, Roden RB, Lowy DR, Kast WM, Schiller JT. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV-16 tumor model. Proc Natl Acad Sci USA 1998;95:1800-5.
43. Schafer K, Muller M, Faath S, Henn A, Osen W, Zentgraf H, Benner A, Gissmann L, Jochmus I. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: Induction of cytotoxic T cells and specific tumor protection. Int J Cancer 1999;81:881-8.
44. Shi W, Liu J, Huang Y, Qiao L. Papillomavirus pseudovirus: A novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses. J Virol 2001;75:10139-48.
45. Londono LP, Chatfield S, Tindle RW, Herd K, Gao XM, Frazer I, Dougan G. Immunization of mice using Salmonella typhimurium expressing human papillomavirus type 16 E7 epitopes inserted into hepatitis B virus core antigen. Vaccine 1996;14:545-52.
46. Lamikanra A, Pan ZK, Isaacs SN, Wu TC, Paterson Y. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different foms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site. J Virol 2001;75:9654-64.
47. Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16(HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 2001;167:6471-9.
48. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Rice CM, Ling M, Wu TC. Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. J Immunol 2001;166:6218-26.
49. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M, Wu TC. Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type I VP22 protein to antigen. J Virol 2001;75:2368-76.
50. Park SF, Stewart GS. High-efficiency transformation of Listeria monocytogenes by electroporation of penicillin-treated cells. Gene 1990;1:129-32.
51. Tindle RW, Fernando GJ, Seterling JC, Frazer IH. A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc Natl Acad Sci USA 1991;88:5887-91.
52. + T cells. Science 1990;248:1227-30.
53. Zijlstra M, Li E, Sajjadi F, Subramani S, Jaenisch R. Germ-line transmission of a disrupted beta 2-microglobulin gene produced by homologous recombination in embryonic stem cells. Nature 1989;342:435-8.
54. + T cells in major histocompatibility complex class II-deficient mice. Science 1991;253:1417-20.
55. Feltkamp MC, Smis HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melief CJ, Kast WM. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993;23:2242-9.
56. b,d,k). J Immunol 1998;161:1094-103.
57. Paterson Y, Ikonomidis G. Recombinant Listeria monocytogenes cancer vaccines. Curr Opin Immunol 1996;8:664-9.
58. Goossens PL, Montixi C, Saron MF, Rodriguez M, Zavala F, Milon G. Listeria monocytogenes: A live vector able to deliver heterologous protein within the cytosol and to drive a CD8 dependent T cell response. Biologicals 1995;23:135-43.
59. Kaufmann SH. Immunity to intracellular bacteria. Annu Rev Immunol 1993;11:129-63.
60. Rose RC, Lane C, Wilson S, Suzich JA, Rybicki E, Williamson AL. Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies. Vaccine 1999;17:2129-35.